Standard antidepressants help many people, but roughly one in three patients treated for depression do not respond adequately to two or more of them. That pattern has a clinical name: difficult-to-treat depression. For those patients, SPRAVATO® (esketamine, a prescription nasal spray medication) offers a treatment path built on a fundamentally different neurological mechanism than anything they have likely tried before.
What Difficult-to-Treat Depression Actually Means
Difficult-to-treat depression is not a sign that depression is permanent or that a patient has failed. Clinically, it refers to depression that has not responded adequately to at least two antidepressant medications taken at appropriate doses for an appropriate duration. The regulatory term used in the FDA approval is “treatment-resistant depression,” and both terms describe the same clinical picture: a patient who has done everything right, tried what was recommended, and is still struggling.
The reason this matters is that standard antidepressants work by increasing the availability of neurotransmitters (chemical messengers in the brain) such as serotonin, norepinephrine, or dopamine. These medications are effective for many patients. But they operate on a specific set of neurological pathways, and depression is not a single-pathway condition. When depression persists through multiple adequate antidepressant trials, the biology involved often extends beyond those pathways into systems that standard medications do not directly address.
At Catalyst Psychiatry, we see patients who have been through years of this experience. They have tried different medications, adjusted doses, pushed through side effects, and still found themselves in the same place. That history is not evidence of a prognosis. It is clinical data that points toward what to look at next.
How SPRAVATO® Works Differently Than Standard Antidepressants
SPRAVATO® targets the N-methyl-D-aspartate receptor, commonly called the NMDA receptor, which is part of the glutamate system. Glutamate is the brain’s primary excitatory neurotransmitter, and the glutamate system plays a significant role in synaptic plasticity, which refers to the brain’s capacity to reorganize and form new neural connections (National Institutes of Health). By acting on this system rather than the serotonin or norepinephrine pathways, SPRAVATO® works through a mechanism that is distinct from conventional antidepressants at a neurological level.
The U.S. Food and Drug Administration approved SPRAVATO® for adults with treatment-resistant depression, making it the first nasal spray medication of its kind for this indication (U.S. Food and Drug Administration). The FDA was also transparent that the exact mechanism by which SPRAVATO® produces its antidepressant effects is not fully understood. What is established is that it acts on a different receptor system than the medications most patients with difficult-to-treat depression have already tried, and that difference carries real clinical significance for this population.
SPRAVATO® is not a first-line treatment. It is specifically designed for patients who have already been through standard options without adequate relief. That focus is what makes it relevant to patients in the Corvallis and Willamette Valley area who are asking what comes next.
SPRAVATO® Treatment at Our Corvallis Practice
Who May Be a Candidate
SPRAVATO® is FDA-approved for adults with difficult-to-treat depression (treatment-resistant depression) and, as a separate indication, for adults with major depressive disorder (MDD) and active suicidal ideation. If you are currently experiencing thoughts of self-harm or suicide, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.
Not every patient with difficult-to-treat depression is a candidate for SPRAVATO®. Certain medical and psychiatric histories affect whether the treatment is appropriate, including a history of substance dependence, unstable cardiovascular conditions, and other factors. Our providers approach every evaluation with that in mind. The candidacy assessment is part of the consultation process, not an afterthought, and results vary by individual.
What Treatment Looks Like at Our Office
SPRAVATO® is not a medication you take at home. It is self-administered as a nasal spray in a certified clinical setting, under direct medical supervision, and you remain at the clinic for monitoring during and for at least two hours after each dose. Catalyst Psychiatry is a certified SPRAVATO® treatment center, which means we are authorized to administer this treatment and trained to monitor for the temporary effects it can produce.
The supervised model exists because SPRAVATO® can cause transient effects during the monitoring window, including dissociation (a feeling of detachment from your thoughts or surroundings), dizziness, sedation, and nausea. These effects are typically temporary and resolve within the observation period. We monitor blood pressure before each session and throughout the observation window. You will need to arrange transportation home after each session, as driving is not permitted until the following day.
Your first visit to our office is a consultation rather than a treatment session. During that appointment, we review your medical history, conduct our own clinical assessment, and verify your insurance coverage. If SPRAVATO® is recommended as part of your treatment plan, we work through the enrollment process with you and answer any questions you have before any sessions begin. Nothing moves forward without that conversation happening first, and the decision about whether to proceed is yours.
Insurance, Cost, and Two Concerns Worth Addressing
SPRAVATO® is covered by most insurance plans, and insurance verification is part of our consultation process before any treatment is recommended. We are in-network with Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield. At this time, we are not accepting Medicare, Medicare Advantage plans, or Oregon Health Plan for SPRAVATO® treatment.
Most patients who consider SPRAVATO® raise two concerns: the time commitment of spending two or more hours at a clinic after each session, and the nature of the medication itself. Both are legitimate, and we address them directly during consultation. The monitoring requirement is not administrative — it exists because the temporary effects SPRAVATO® can cause are real, and having a clinical team present is what makes it safe to offer. As for the medication: SPRAVATO® uses esketamine administered at therapeutic doses in a supervised clinical setting under FDA protocols, which is clinically distinct from non-medical use. This is an FDA-approved psychiatric medication available only through certified providers.
Frequently Asked Questions About SPRAVATO® for Depression
What is the difference between difficult-to-treat depression and regular depression?
Difficult-to-treat depression is a clinical designation that applies when depression has not responded adequately to two or more antidepressant medications taken at appropriate doses for appropriate durations. It does not mean depression cannot be treated; it means that the neurological mechanisms involved may require a different therapeutic approach than first-line antidepressants provide. A thorough psychiatric evaluation is the starting point for understanding what options may be appropriate.
Why does SPRAVATO® work when antidepressants haven’t?
Standard antidepressants primarily target serotonin, norepinephrine, or dopamine pathways. SPRAVATO® acts on NMDA receptors in the glutamate system, which is a different neurological pathway entirely. For patients whose depression involves mechanisms beyond those targeted by conventional antidepressants, SPRAVATO® addresses a system that other medications have not reached. The exact mechanism is still being studied, and results vary by individual.
Does insurance cover SPRAVATO® treatment?
SPRAVATO® is covered by most major insurance plans. Coverage criteria vary by plan and typically require documentation of prior antidepressant trials. We verify coverage during your consultation appointment before any treatment begins, so you have a clear picture of what your plan covers.
What happens during a SPRAVATO® session at Catalyst Psychiatry?
Each session takes place in our Corvallis office. You self-administer the SPRAVATO® nasal spray under the observation of our clinical team. We monitor your blood pressure before the session and throughout the observation period that follows, which lasts at least two hours. You should plan not to drive that day and to have transportation arranged. Temporary effects during the observation window can include dizziness, nausea, dissociation, and sedation; these typically resolve before you leave.
How do I find out if I am a candidate for SPRAVATO®?
The candidacy assessment takes place during a consultation at our office. We review your full medical and psychiatric history, conduct our own clinical evaluation, and discuss whether SPRAVATO® may be appropriate given your specific situation. There is no commitment required to have that conversation. If SPRAVATO® is not the right fit, we discuss what other options may be relevant to your history and goals.
Key Takeaways
- Difficult-to-treat depression is a clinical designation for depression that has not responded adequately to two or more antidepressant trials, not a statement about prognosis or effort.
- SPRAVATO® targets NMDA receptors in the glutamate system, a mechanism that differs from standard antidepressants, which act primarily on serotonin, norepinephrine, or dopamine pathways.
- SPRAVATO® is FDA-approved for adults with treatment-resistant depression and, separately, for adults with major depressive disorder and active suicidal ideation.
- Treatment sessions take place in our Corvallis office under direct medical supervision; Catalyst Psychiatry is a certified SPRAVATO® treatment center.
- SPRAVATO® is covered by most insurance plans; we verify coverage during the consultation appointment before any treatment is recommended, and results vary by individual.
For patients in the Corvallis and Willamette Valley area who have tried multiple antidepressants without adequate relief, SPRAVATO® offers a clinically distinct option backed by FDA approval and a specific neurological rationale. The first step is a consultation at our office, where we review your history, confirm whether you may be a candidate, and walk through what treatment would look like in practical terms. Call us at 541-730-4400 or reach out through our website to schedule that conversation. Your treatment decisions are yours to make, and we are here to give you the information to make them well.
References
U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression, available only through a restricted program. https://www.fda.gov/…
National Institutes of Health. Ketamine and the glutamate system: Mechanisms of antidepressant action. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
Mayo Clinic. Depression (major depressive disorder): Symptoms and causes. https://www.mayoclinic.org/…
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® treatment, like all psychiatric treatments, should only be pursued under the supervision of a licensed psychiatric provider who is familiar with your full medical and psychiatric history. Individual results vary, and not all patients respond to SPRAVATO®. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.